(Q34635942)

3 August 2017

1 reference

title

Calcitonin for the long-term prevention and treatment of postmenopausal osteoporosis (English)

1 reference

postmenopausal osteoporosis

3 August 2017

0 references

1 reference

Body JJ

1

1 reference

3 August 2017

language of work or name

1 reference

1 May 2002

1 reference

3 August 2017

1 reference

3 August 2017

volume

30

1 reference

3 August 2017

issue

5 Suppl

1 reference

3 August 2017

page(s)

75S-79S

1 reference

Salmon calcitonin in the prevention of bone loss at perimenopause.

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2802%2900715-9

7 January 2021

Regulation of lymphocyte calcitonin receptors by interleukin-1 and interleukin-6

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2802%2900715-9

7 January 2021

Calcitonin receptors on circulating normal human lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2802%2900715-9

7 January 2021

A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2802%2900715-9

7 January 2021

Bone turnover in postmenopausal osteoporosis. Effect of calcitonin treatment

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2802%2900715-9

7 January 2021

The Effect of Raloxifene on Risk of Breast Cancer in Postmenopausal Women

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2802%2900715-9

7 January 2021

Intranasal salmon calcitonin for the prevention and treatment of postmenopausal osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2802%2900715-9

7 January 2021

Calcitonin increases the concentration of insulin-like growth factors in serum-free cultures of human osteoblast-line cells

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2802%2900715-9

7 January 2021

An effective regimen of intranasal salmon calcitonin in early postmenopausal bone loss

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2802%2900715-9

7 January 2021

Clinical significance of antibodies against calcitonin

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2802%2900715-9

7 January 2021

Long-term calcitonin therapy in postmenopausal osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2802%2900715-9

7 January 2021

Evidence for efficacy of drugs affecting bone metabolism in preventing hip fracture

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2802%2900715-9

7 January 2021

Effect of calcitonin on vertebral and other fractures

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2802%2900715-9

7 January 2021

Synthetic human calcitonin in postmenopausal osteoporosis: a placebo-controlled, double-blind study

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2802%2900715-9

7 January 2021

Prevention of bone loss in early nonsurgical and nonosteoporotic high turnover patients with salmon calcitonin: the role of biochemical bone markers in monitoring high turnover patients under calcitonin treatment.

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2802%2900715-9

7 January 2021

Effects of salmon calcitonin in postmenopausal osteoporosis: a controlled double-blind clinical study

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2802%2900715-9

7 January 2021

Effects of salmon calcitonin on the bone loss induced by ovariectomy

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2802%2900715-9

7 January 2021

A clinical trial on the effects of a combination of elcatonin (carbocalcitonin) and conjugated estrogens on vertebral bone mass in early postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2802%2900715-9

7 January 2021

Dose-response bioactivity and bioavailability of salmon calcitonin in premenopausal and postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2802%2900715-9

7 January 2021

Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis: a dose-response study

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2802%2900715-9

7 January 2021

Discontinuous calcitonin treatment of established osteoporosis--effects of withdrawal of treatment

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2802%2900715-9

7 January 2021

Effect of salcatonin given intranasally on early postmenopausal bone loss

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2802%2900715-9

7 January 2021

Nasal calcitonin for treatment of established osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2802%2900715-9

7 January 2021

Endogenous production of specific antibodies does not decrease hypocalcemic response to calcitonin in young rabbits

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2802%2900715-9

7 January 2021

1-Year controlled randomised trial of prevention of early postmenopausal bone loss by intranasal calcitonin

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2802%2900715-9

7 January 2021

Long-term (3 years) prevention of trabecular postmenopausal bone loss with low-dose intermittent nasal salmon calcitonin

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2802%2900715-9

7 January 2021

Relationship between whole plasma calcitonin levels, calcitonin secretory capacity, and plasma levels of estrone in healthy women and postmenopausal osteoporotics

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2802%2900715-9

7 January 2021

A double-blind, placebo-controlled, dose-finding trial of intermittent nasal salmon calcitonin for prevention of postmenopausal lumbar spine bone loss

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2802%2900715-9

7 January 2021

Prevention of osteoporosis with nasal salmon calcitonin: effect of anti-salmon calcitonin antibody formation

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2802%2900715-9

7 January 2021

A 5-year controlled randomized study of prevention of postmenopausal trabecular bone loss with nasal salmon calcitonin and calcium

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2802%2900715-9

7 January 2021

Salmon calcitonin reduces vertebral fracture rate in postmenopausal crush fracture syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2802%2900715-9

7 January 2021

Total and regional bone mineral content and fracture rate in postmenopausal osteoporosis treated with salmon calcitonin: a prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2802%2900715-9

7 January 2021

[Treatment of primary osteoporosis with calcium and salmon calcitonin]

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2802%2900715-9

7 January 2021

Morning or evening administration of nasal calcitonin? Effects on biochemical markers of bone turnover

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2802%2900715-9

7 January 2021

Effect of nasal salmon calcitonin on bone remodeling and bone mass in postmenopausal osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2802%2900715-9

7 January 2021

Acute effects of nasal salmon calcitonin on calcium and bone metabolism

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2802%2900715-9

7 January 2021

Effect of different doses of nasal salmon calcitonin on bone mass

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2802%2900715-9

7 January 2021

Long- and short-term side effects and safety of calcitonin in man: a prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2802%2900715-9

7 January 2021

10.1016/S8756-3282(02)00715-9

Identifiers

DOI

1 reference

3 August 2017

1 reference